Investment
Features
FeesSafety
Academy
More
Pluang+

Canton Network launches Proof of Transfer API for private asset transaction verification

Others
29 Sep 2026
Crypto Economy
View Source
Neutral
Canton Network launches Proof of Transfer API for private asset transaction verification

Canton Network has introduced a new Proof of Transfer API that enables users to verify transactions involving private assets without revealing sensitive information. This innovation enhances privacy and security in asset verification processes, allowing for confidential data protection while confirming transaction status. The development is significant for users and platforms prioritizing privacy in blockchain transactions, potentially setting a new standard for secure asset verification.

The story on Canton Network's new Proof of Transfer API for private asset verification is presented here with Pluang's cryptocurrency market data as context. For readers following major cryptocurrencies, here is Pluang's market snapshot as of Sep 30, 2026 01:02 WIB: out of 50 priced major cryptocurrencies, 15 rose and 34 fell today. Notable movers include COMP (Compound) at Rp437.893 with a 1-day change of +3.56%, LTC (Litecoin) at Rp1.204.552 down -3.15%, and ONE (Harmony) at Rp44 down -2.88%.

More News

Micron projects record $51.33B revenue driven by AI memory demand, with EPS soaring to $31.72 this quarter.

Micron projects record $51.33B revenue driven by AI memory demand, with EPS soaring to $31.72 this quarter.

Micron Technology is set to report record quarterly revenue of up to $51.33 billion, fueled by strong demand for high-bandwidth memory in the AI market. Earnings per share are expected to jump significantly to around $31.72, compared to $3.03 last ye...

Company Fundamentals
Bullish
22 minutes ago
Sangoma beats EPS estimates but misses revenue; acquisition deal boosts shares 35%.

Sangoma beats EPS estimates but misses revenue; acquisition deal boosts shares 35%.

Sangoma Technologies reported a smaller-than-expected loss with an EPS of -$0.08, beating analyst estimates of -$2.19, though its revenue of $48.55 million slightly missed expectations. Despite ongoing profitability challenges reflected in a negative...

Company Fundamentals
Bullish
2 hours ago
Iovance Biotherapeutics raises 2026 revenue forecast with strong Q2 sales and analyst optimism.

Iovance Biotherapeutics raises 2026 revenue forecast with strong Q2 sales and analyst optimism.

Iovance Biotherapeutics has increased its full-year 2026 revenue guidance to $410-$420 million, reflecting nearly 60% growth driven by strong U.S. demand for its cancer therapy Amtagvi, which generated $91 million in Q2 sales. Analyst Joseph Pantgini...

Analyst Insights
Bullish
3 hours ago
uniQure shares drop 37% after mixed results in Huntington's gene therapy trial

uniQure shares drop 37% after mixed results in Huntington's gene therapy trial

uniQure's stock fell sharply by 37% following a four-year update on its AMT-130 gene therapy for Huntington's disease, which showed reduced effectiveness from 80% at three years to 44% at four years, failing to reach statistical significance. Despite...

Market News
Bearish
3 hours ago
Gold faces pressure from rising yields and a strong dollar, with ETF demand its main support.

Gold faces pressure from rising yields and a strong dollar, with ETF demand its main support.

Gold prices are under significant pressure due to a break below $4,230, rising U.S. Treasury yields, and a stronger dollar, which have triggered renewed selling. Despite these headwinds, gold ETF holdings continue to recover, suggesting some investor...

Market News
Bearish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App